• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Feline vaccinal sarcomas (Proceedings)

August 1, 2010
Mark Cousins, DVM, DABVP (feline)

The recognition of the development of potentially malignant tumors arising from injection sites became one of the most significant events in veterinary medicine in the 1980's and beyond. So significant, in fact, that it caused an entire profession to re-evaluate the way preventative medicine should be considered from a medical and an economic perspective.

The recognition of the development of potentially malignant tumors arising from injection sites became one of the most significant events in veterinary medicine in the 1980's and beyond. So significant, in fact, that it caused an entire profession to re-evaluate the way preventative medicine should be considered from a medical and an economic perspective.

This presentation discusses the orienting of a veterinary practice towards enhancing the feline component of practice: how to position a practice so that feline clients understand that their veterinarian manages a business sensitive to the needs of cats and those clients that own them. The demographics and psychographics of the feline client will be discussed in the process of discussing the business of cats.

Advertisement

Historically, this presentation reviews the historical epidemiology leading up to the recognition of the phenomenon of FVAS . The pathogenesis of FVAS will also be discussed in detail. Chronic inflammatory response in the subcutis of the cat has been documented as one of the, if not the, most important triggering mechanisms in the development of these sarcomas. Chronic inflammation alters the genetic control of cell death with the resulting formation of abnormal clones of cells being produced. This begins the cycle of the development of FVAS. Adjuvants (chemicals added to vaccines to increase the body's response to the antigen in the vaccine) can be the principle cause of the production of this chronic inflammatory response in the subcutaneous tissue of cats.

Multimodal (surgery combined with radiotherapy and/or chemotherapy) therapeutic strategies stand the best chance for a better therapeutic outcome for FVAS. However, early recognition of these tumors and the early strategy the veterinarian employs for diagnosis/removal can be critical to case outcome. But, unless aggressive diagnostic and therapeutic plans are employed, the prognosis is generally not good.

Prevention is definitely the best medicine in this disease. Recommendations by the Feline Vaccinal Task Force and the American Association of Feline Practitioners state that vaccines should produces as little inflammation as possible to prevent these tumors from occurring.

Related Content:

OncologyFeline Medicine
Combining the best of private practice with clinic spay/neuter care
Combining the best of private practice with clinic spay/neuter care
Constant-rate infusions for feline pain
Constant-rate infusions for feline pain
5 feline exam tips for new graduates
5 feline exam tips for new graduates

Advertisement

Latest News

Four ways to curb no shows

FDA and European Union expand Mutual Recognition Agreement to include animal drugs

Successful tolerability study of CBD products for dogs

Second annual 'Dog Days of Summer' adoption event to take place in Michigan

View More Latest News
Advertisement